肺癌

有意团购印度易瑞沙 印度特罗凯 印度力比泰 请加入我们的群
官方QQ群1：26438631  5100806  或QQ:3 5 7 6 8 7 5 注明 www.feiai88.com！

　　对病情一知半解而延误医治，是肺癌患者最普遍的现象。香港大学一项亚太区肺癌认知调查，证实人们对肺癌的无知。通常，从轻微的干咳拖延到咳出血才去检查，确诊时已是肺癌的第三或四期，癌细胞已扩散到其他器官。

　　去年4月底，在泰国曼谷举行的肺癌治疗趋势研讨会中，香港大学社会科学研究中心发表了首次进行的“亚太区肺癌认知”调查，数据证实人们对肺癌的“无知”。

　　在亚洲国家中，肺癌是中国大陆及香港、中国台湾、韩国、新加坡的头号杀手，可是人们却对这种致命癌症缺乏普遍的认识。上述研究调查显示：

　　·70%的人没意识到肺癌是癌症致命的主因。

　　·62%受访者只有少数，甚至不认识肺癌。

　　·约80%低估或不知因肺癌夺命的比率。

　　·超过50%的人不认识任何肺癌的症状。
　　一知半解延误医治
　　对病情一知半解而延误医治，是最普遍的现象。通常，从轻微的干咳拖延到咳出血才去检查，确诊时已是肺癌的第三或四期，癌细胞已扩散到其他器官，难以进行手术切除之余，即使是放射化疗的效果也不理想，而采用标靶治疗药物，暂时是控制治疗与提高存活率最有效的方法。
　　肺癌第一期的5年存活率高达90%，第二期的存活率已降至50%，晚期则更低。肺癌已非“60岁吸烟者的专利”，在亚太地区的肺癌患者中，年轻的非吸烟女性患腺性肿瘤肺癌的比率逐渐上升，遗传基因、二手烟、空气污染等，都是可能加促的因素，而患者也容易因忽视症状而延医。
　　肺癌第III或IV期，癌细胞已扩散到其他器官，无法接受根治性手术。常规的联合放、化疗的效果也不理想。
　　肺癌症状与药物治疗
　　肺癌出现的症状如持续咳嗽、咳血、气促、胸痛等，多数已代表肺部肿瘤扩散至可能影响其他器官的地步，显示非早期病情。现阶段只能说，及早戒烟、定期检查身体，是防范肺癌的方法。戒烟5年，患肺癌几率减半，戒烟16年以上，患肺癌几率跟不吸烟者一样。目前，医学界暂时知道的是，应用标靶治疗肺癌药“吉非替尼”(Gefitinib)时，曾吸烟的肺癌者的药物反应，远不如从不吸烟的肺癌患者。
　　上述研讨会分析“吉非替尼”的“IDEAL”和“ISEL”的研究报告指出，非吸烟的亚裔“非小细胞”肺癌患者(尤其是女性)，对于药物的反应，相较于白人理想两三倍，有些病人甚至用药3年仍然存活。
　　“IDEAL”：“吉非替尼”第二期临床研究显示，共有210名“非小细胞”肺癌患者参与，结果患者的平均生存中位数为7.6个月;1年后的生存率约30%。但是，参与研究的日本肺癌患者每日服用250克药物的组别中，平均生存中位数却显著增至13.8个月，1年后的生存率也增高至57%。
　　“ISEL”：“吉非替尼”第三期临床研究显示，1692名曾进行化疗的晚期“非小细胞”肺癌病人参与，结果发现药物用在亚裔病人的效果较佳，较安慰剂组别的生存中位数5.1个月多出4个月;而从不吸烟者的肺癌病人，用药后的生存中位数也较安慰剂的组别增加2.8个月。
　　肺癌细胞分两种：小细胞和非小细胞，后者占整体肺癌个案的大多数。癌细胞表面的“EGFR”(表皮生长因子受体)与生长因子结合后，会刺激细胞受体入面的酵素“Tyrosine Kinase”，加速细胞的生长与分裂，而药物“吉非替尼”的功效，则在于抑制酵素发挥作用，制止细胞分裂。当中腺癌反应明显比其他肺癌理想，研究也证实，具有“EGFR”突变基因产生的表皮生长因子受体，对药物反应最为理想;而腺癌已找到两三个生物标记，可使细胞对药物反应更敏感。至于无“EGFR”突变基因的肺癌患者，用药后的良性反应的几率只有一两成。

看过此文章的朋友还看过
易瑞沙(IRESSA)中文说明      特罗凯(Tarceva)中文说明书
印度易瑞沙真假辨别方法    

==== 汉译英 ====

Superficial understanding of the disease to delay treatment, lung cancer is the most common phenomenon. University of Hong Kong an Asia-Pacific lung cancer awareness survey, confirmed that people's ignorance of lung cancer. Typically, the delay from mild cough to cough blood was to be examined, diagnosed when the third or 4 lung cancer, cancer has spread to other organs.

Last year, by the end of April, in Bangkok, Thailand at the treatment of lung cancer trends in the seminar, Hong Kong University Social Sciences Research Center published the first time the "Asia-Pacific lung cancer awareness" survey, the data confirm that people of lung cancer "ignorance."

In Asian countries, lung cancer is the Chinese mainland and Hong Kong, China Taiwan, South Korea, Singapore, the number one killer, but one bite the lack of general awareness of fatal cancer. The research shows that:

* 70% of people are not aware that lung cancer is the main cause of fatal cancer.

62% of the respondents only a few, or even do not know of lung cancer.

* About 80% underestimate or do not know the ratio of lung cancer killer.

* More than 50% of people do not know any of the symptoms of lung cancer.

A smattering of knowledge delayed healing

Superficial understanding of delayed treatment of the disease is the most common phenomenon. Typically, the delay from mild cough to cough blood was to be examined, diagnosed when the third or 4 lung cancer, cancer cells have spread to other organs, apart from surgical resection is difficult, even if the effect of chemotherapy, radiation is not an ideal , while the use of target therapy to temporarily control the treatment and improve survival of the most effective method.

The first phase of lung cancer 5-year survival as high as 90%, the second phase of the survival rate has dropped to 50%, late lower. Of lung cancer are not the "60-year-old smokers patent" in the Asia Pacific region, lung cancer patients, the young non-smoking women suffering from glandular tumors gradually increased the rate of lung cancer, genetics, second-hand smoke, air pollution, are likely to Add promoting factors, while patients are susceptible to the symptoms and seek medical neglect.

The first phase III or IV lung cancer, cancer cells have spread to other organs, can not accept radical surgery. Conventional combined radiotherapy and chemotherapy is not satisfactory results.

Lung cancer symptoms and drug treatment

Of lung cancer symptoms such as persistent cough, hemoptysis, shortness of breath, chest pain, etc. on behalf of the majority of lung cancer spread to the point that may affect other organs, indicating the non-early disease. Can only say that at this stage, early smoking cessation, regular medical check-ups, is to prevent lung cancer approach. Quit smoking five years, the risk of lung cancer risk by half, quit smoking more than 16 years, with the risk of lung cancer as non-smokers. At present, the medical profession being aware that the application target for lung cancer drug "Gefitinib" (Gefitinib), he had lung cancer who smoke drug reactions, much less in patients with lung cancer never smoked.

The seminar analysis "gefitinib" and "IDEAL" and the "ISEL" the study reported that non-smoking Asian "non-small cell" lung cancer patients (especially women), for drug response, compared with two or three times the white ideal, some patients still alive 3 years and even medication.

"IDEAL": "Gefitinib" Phase II clinical studies have shown that a total of 210 "non-small cell" lung cancer patient participation, resulting in median survival of patients with a median of 7.6 months; a survival rate of about 30 years later %. However, participated in the study of Japanese lung cancer patients taking a daily 250 grams of drugs group, the average median survival was significantly increased to 13.8 months, one year after the survival rate has increased to 57%.

"ISEL": "Gefitinib" Phase III clinical studies have shown that 1692 had chemotherapy of advanced "non-small cell" lung cancer patients participate in and found that drug use in Asian patients with better results than the placebo group else median survival of 5.1 months over a 4 months; and never-smokers of lung cancer patients, the median survival after treatment than the placebo group is also an increase of 2.8 months.

Lung cancer cells in two ways: small cell and non-small cell lung cancer cases in which the majority of the total. The surface of cancer cells "EGFR" (epidermal growth factor receptor) and growth factor binding, it will stimulate the cell receptor into the surface of the enzyme "Tyrosine Kinase", to accelerate cell growth and division, while the drug "gefitinib" in effectiveness lies in inhibiting enzymes play a role in stopping cell division. Were significantly higher than those of other lung cancer, adenocarcinoma of the ideal response, research has also confirmed that with the "EGFR" mutation resulting from the epidermal growth factor receptor, for the most ideal drug reaction; and adenocarcinoma have been found 23 biomarkers will enable the cells to drugs response more sensitive. Regarding the "EGFR" mutant gene of lung cancer patients after treatment of benign response rate of only one or two into.